Successful Long-Term Management of Psoriatic Arthritis With Apremilast Following Multiple Myeloma Diagnosis During Etanercept Therapy: A 20-Month Follow-up
Restricted accessLetterFirst published online 2026
Successful Long-Term Management of Psoriatic Arthritis With Apremilast Following Multiple Myeloma Diagnosis During Etanercept Therapy: A 20-Month Follow-up
KeatingGM.Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2017;77(4):459-472. doi:10.1007/s40265-017-0709-1
2.
SchaferP.Apremilast: mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583-1590. doi:10.1016/j.bcp.2012.01.001
3.
SandhuVKEderLYeungJ.Apremilast and its role in psoriatic arthritis. G Ital Dermatol Venereol. 2020;155(4):386-399. doi:10.23736/S0392-0488.20.06640-7
4.
ChoiBParkHJSongYK, et al. The risk of newly diagnosed cancer in patients with rheumatoid arthritis by TNF inhibitor use: a nationwide cohort study. Arthritis Res Ther. 2022;24(1):191. doi:10.1186/s13075-022-02868-w
5.
TokarevaKPetersonACBaraffA, et al. Use of disease modifying anti-rheumatic drugs and risk of multiple myeloma in US Veterans with rheumatoid arthritis. BMC Rheumatol. 2025;9(1):7. doi:10.1186/s41927-025-00457-3
6.
KamiyaKYamaguchiYSaekiH, et al. Prospective, open-label, multicenter study of apremilast as maintenance therapy for psoriasis patients in remission with biologics. J Dermatol. 2025;53:71-85. doi:10.1111/1346-8138.17968
